Condition (MeSH)
Polymorphic Catecholaminergic Ventricular Tachycardia
ClinicalTrials.gov lists 16 trials for Polymorphic Catecholaminergic Ventricular Tachycardia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Polymorphic Catecholaminergic Ventricular Tachycardia itself; the rest are tagged with a narrower condition beneath it.
When did Polymorphic Catecholaminergic Ventricular Tachycardia trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 1 |
| 2013 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polymorphic Catecholaminergic Ventricular Tachycardia trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Not applicable | 3 |
| Observational | 10 |
How many Polymorphic Catecholaminergic Ventricular Tachycardia trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 7 |
| Enrolling by invitation | 2 |
| Completed | 7 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polymorphic Catecholaminergic Ventricular Tachycardia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Agiana Pharmaceuticals | 1 |
| Cardurion Pharmaceuticals, Inc. | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| Solid Biosciences Inc. | 1 |
Which drugs are being tested for Polymorphic Catecholaminergic Ventricular Tachycardia? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Flecainide | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Atropine 1% | 1 |
| Beta Blocker | 1 |
| AGP100 | 1 |
| CRD-4730 | 1 |
| MRI | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Polymorphic Catecholaminergic Ventricular Tachycardia trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Allergic Reaction requiring Hospitalization | 1 | 1 |
| Back pain requiring Surgery | 1 | 1 |
| Implantable Cardioverter-Defibrillator Infection | 1 | 1 |
| Suicidal Ideation | 1 | 1 |
| Supraventricular Tachycardia | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Polymorphic Catecholaminergic Ventricular Tachycardia? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. | JAMA | 2024 | No |
| Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. | JAMA cardiology | 2022 | No |
| Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology | 2020 | No |
| Bilateral continuous erector spinae plane blocks for sternotomy in a pediatric cardiac patient. | Journal of clinical anesthesia | 2018 | No |
| Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. | JAMA cardiology | 2017 | No |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.